Celyad SA (CYAD) - Total Liabilities
Based on the latest financial reports, Celyad SA (CYAD) has total liabilities worth €8.80 Million EUR (≈ $10.29 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Celyad SA - Total Liabilities Trend (2010–2024)
This chart illustrates how Celyad SA's total liabilities have evolved over time, based on quarterly financial data. See CYAD net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Celyad SA Competitors by Total Liabilities
The table below lists competitors of Celyad SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
South Malaysia Industries Bhd
KLSE:4375
|
Malaysia | RM27.74 Million |
|
Burford Capital Limited
LSE:BUR
|
UK | GBX3.50 Billion |
|
Conquest Resources Ltd
V:CQR
|
Canada | CA$87.98K |
|
LiqTech International Inc
NASDAQ:LIQT
|
USA | $16.91 Million |
|
Gaya Abadi Sempurna
JK:SLIS
|
Indonesia | Rp92.90 Billion |
|
Cherry AG
XETRA:C3RY
|
Germany | €73.87 Million |
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
USA | $80.25 Million |
|
Yoshitsu Co Ltd ADR
NASDAQ:TKLF
|
USA | $155.00 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Celyad SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CYAD company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celyad SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celyad SA (2010–2024)
The table below shows the annual total liabilities of Celyad SA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €26.05 Million ≈ $30.45 Million |
+161.05% |
| 2023-12-31 | €9.98 Million ≈ $11.67 Million |
-35.20% |
| 2022-12-31 | €15.40 Million ≈ $18.00 Million |
-57.58% |
| 2021-12-31 | €36.30 Million ≈ $42.44 Million |
+3.46% |
| 2020-12-31 | €35.09 Million ≈ $41.02 Million |
-20.64% |
| 2019-12-31 | €44.22 Million ≈ $51.69 Million |
+14.23% |
| 2018-12-31 | €38.71 Million ≈ $45.26 Million |
+28.64% |
| 2017-12-31 | €30.09 Million ≈ $35.18 Million |
-37.21% |
| 2016-12-31 | €47.92 Million ≈ $56.02 Million |
-0.27% |
| 2015-12-31 | €48.05 Million ≈ $56.18 Million |
+177.89% |
| 2014-12-31 | €17.29 Million ≈ $20.22 Million |
+11.65% |
| 2013-12-31 | €15.49 Million ≈ $18.11 Million |
+2.85% |
| 2012-12-31 | €15.06 Million ≈ $17.60 Million |
+149.42% |
| 2011-12-31 | €6.04 Million ≈ $7.06 Million |
-31.43% |
| 2010-12-31 | €8.80 Million ≈ $10.29 Million |
-- |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more